Biomarkers, atherosclerosis and cardiovascular events

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 5, 2008, Pages 619-622

  Rosenson, Robert S ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; BENAZEPRIL; BIOLOGICAL MARKER; CANNABINOID 1 RECEPTOR ANTAGONIST; CHOLESTEROL; EZETIMIBE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; PIOGLITAZONE; PLACEBO; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; SIMVASTATIN; TELMISARTAN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CARDIOVASCULAR AGENT;

ANXIETY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DEFIBRILLATION; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MENTAL DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RESUSCITATION; RISK BENEFIT ANALYSIS; SIDE EFFECT; CLINICAL OBSERVATION; CLINICAL STUDY; DIABETES MELLITUS; DIAGNOSIS; DRUG COMBINATION; FEMALE; HYPERCHOLESTEROLEMIA; MALE; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 47149108898     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.5.619     Document Type: Conference Paper

References (12)

1. Kastelein JJP, Akdim F, Stroes ES G et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
2. Smilde TJ, van Wissen S, Awollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357, 577-581 (2001).
3. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299, 1561-1573 (2008).
4. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA 296, 2572-2581 (2006).
5. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
6. Bertrand OF, Poirier P, Rinfret S et al. Results of a multicenter randomized double-blind placebo controlled study to assess the benefit and safety of rosiglitazone in preventing atherosclerosis progression after coronary artery bypass surgery in Type 2 diabetes. Presented at: American College of Cardiology 57th Annual Scientific Session. Chicago, IL, USA, 29 March-1 April 2008.
7. Nissen SE, Nicholls SJ, Wolski K et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299, 1547-1560 (2008).
8. Gueyffier F, Bulpitt C, Boissel J-P et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 353, 793-796 (1999).
9. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N. Engl J. Med. DOI: NEJMoa0801369 (2008) (Epub ahead of print).
10. Jamerson KA, Bakris GL, Wun CC et al. Rationale and design of the Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am. J. Hypertens. 17, 793-801 (2004).
11. Yusuf S, Sleight P, Anderson C et al. Telmisartan, ramipril, or both in patients at high risk for vascular events: for the ONTARGET investigators. N. Engl. J. Med. 358, 1547-1559 (2008).
12. Bardy GH, Lee KL, Mark DB et al. Home use of automated external defibrillators for sudden cardiac arrest. N. Engl. J. Med. DOI: 10.1056/NEJMoa0801651 (2008) (Epub ahead of print).